CD22 and diffuse large B-cell lymphoma: Polatuzumab vedotin (DCDS4501A) and pinatuzumab vedotin (DCDT2980S), MMAE-based ADCs targeting CD79b and CD22, respectively, showed clinical activity in combination with rituximab in relapsed/refractory diffuse large B-cell lymphoma (DLBCL) [81].